Clinical implications of PD-L1 expression in oncogene-driven NSCLC: Differential responses to targeted agents and immune checkpoint inhibitors [0.03%]
驱动基因突变的非小细胞肺癌PD-L1表达的临床意义：靶向药物和免疫检查点抑制剂疗效差异
Xiaoxiao Fan,Chenxi Wei,Minjun Rong et al.
Xiaoxiao Fan et al.
PD-L1 is a reliable biomarker for predicting immunotherapy efficacy in NSCLC patients without driver gene mutations. However, its significance in patients with driver gene-positive tumors remains unclear. This study analyzed 273 patients wi...
Prediction of the individual risk for the development of brain metastases in patients with non-oncogene-addicted non-small cell lung cancer: Real-world data from the German prospective CRISP registry (AIO-TRK-0315) [0.03%]
基于德国前瞻性CRISP登记处（AIO-TRK-0315）的现实世界数据预测非小细胞肺癌患者发生脑转移的个体风险：无原癌基因成瘾型非小细胞肺癌患者的脑转移风险预测
Fabian Acker,Katharina Wenger,Martin Reck et al.
Fabian Acker et al.
Brain metastases (BM) from non-small cell lung cancer (NSCLC) are a relevant cause of morbidity and mortality. This study aims to identify a population at high risk for BM in order to inform personalized follow-up strategies in the future. ...
Coronavirus disease 2019 infection reduces EGFR-TKI efficacy in non-small cell lung carcinoma: Real-world evidence from a multicenter propensity-matched cohort [0.03%]
新型冠状病毒疾病2019感染降低非小细胞肺癌表皮生长因子受体酪氨酸激酶抑制剂疗效：来自多中心倾向匹配队列的证据
Wenjie Tang,Xiaoxuan Hou,Li Li et al.
Wenjie Tang et al.
Coronavirus disease 2019 (COVID-19) remains a global health threat, particularly for patients with cancer, who experience greater susceptibility and worse outcomes. Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) is ...
SGLT2 inhibitors mitigate cardiorenal toxicity and improve survival in type 2 diabetes mellitus patients undergoing antineoplastic therapy: A multicenter retrospective cohort study [0.03%]
钠-葡萄糖协同转运蛋白2抑制剂可减轻接受抗肿瘤治疗的2型糖尿病患者的 cardiorenal毒性并提高其生存率：一项基于多中心回顾性队列的研究
Yueyan Zhao,Yanli Zhang,Mingyue Ju et al.
Yueyan Zhao et al.
Asia faces a rising cancer burden, with type 2 diabetes mellitus (T2DM) prevalence in cancer patients at 24.4% (2.3-fold higher than that of the general population). Antineoplastic therapies (e.g., anthracyclines and vascular endothelial gr...
Prediction of dose reductions and impact of reduced starting doses of CDK4/6i on effectiveness in HR-positive/HER2-negative metastatic breast cancer: Real-world data from the OPAL registry [0.03%]
CDK4/6抑制剂剂量降低的预测及初始剂量降低对HR阳性/HER2阴性转移性乳腺癌疗效影响的现实世界证据：来自OPAL登记处的数据
Patrick Marschner,Kai Ringwald,Marc Thill et al.
Patrick Marschner et al.
Cancer patients prone to toxicities might benefit from dose reduction over fixed-dose recommendations. We develop a predictive index to identify patients with increased probability of dose reduction, intolerable toxicities, or therapy disco...
Methodological reflections on real-world electronic health records analyses in oncology [0.03%]
肿瘤学中基于真实世界电子健康记录分析的方法学思考
Andreas Bjerrum
Andreas Bjerrum
Dynamics of the association between circulating levels of miRNA and pancreatic cancer risk through the years prior to pancreatic cancer diagnosis [0.03%]
胰腺癌发病前几年循环miRNA水平与胰腺癌风险之间关联的动态变化规律研究
Hui Cai,Veronica Wendy Setiawan,Xingyi Guo et al.
Hui Cai et al.
Early diagnosis of pancreatic ductal adenocarcinoma (PDAC) is critical to improving the overall prognosis. However, biomarkers for early diagnosis are lacking. We used pre-diagnostic plasma samples from 1307 PDAC cases and individually matc...
Drug repurposing in oncology: Bridging computational discovery to clinical application [0.03%]
肿瘤学中的药物再利用：从计算发现到临床应用之桥
Sugumar Baskar,N Rajendra Prasad
Sugumar Baskar
Drug repurposing, the identification of new therapeutic applications for existing drugs, has emerged as a pragmatic and cost-efficient strategy to accelerate oncology drug discovery. Faced with rising development costs, protracted timelines...
Sequential personalized neoantigen vaccination following first-line treatments demonstrates safety and efficacy in advanced hepatocellular carcinoma [0.03%]
序贯个性化neo抗原疫苗联合一线疗法治疗晚期肝细胞癌的安全性和有效性研究
Zhixiong Cai,Liman Qiu,Ling Li et al.
Zhixiong Cai et al.
Hepatocellular carcinoma (HCC) has limited therapeutic options in the advanced stages; although first-line combinations of transarterial chemoembolization (TACE) with tyrosine kinase inhibitors (TKIs) and/or programmed cell death protein 1 ...
Cyanotoxin exposure as a novel risk factor for liver fibrosis and steatosis [0.03%]
蓝藻毒素暴露是肝纤维化和脂肪变性的新型危险因素
Brenda Y Hernandez,Xuemei Zhu,Ella Macatugal et al.
Brenda Y Hernandez et al.
Cyanobacteria are ubiquitous environmental bacteria capable of producing cyanotoxins, including potent liver tumor promoters. There is limited knowledge of exposure to cyanotoxins and their potential role in the pathogenesis of liver cancer...